Courses

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC
Oncology

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC

This CME program, derived from content presented at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland, will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Dr. Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers, and associated ...
View Course

Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis
Neurology

Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis

This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will delve into a scientific update on Bruton tyrosine kinase inhibitors (BTKi) to improve outcomes for patients with multiple sclerosis (MS). The expert faculty, Dr. Benjamin Greenberg, will first review recent clinical trial data for BTK inhibitor therapeutics to treat patients with MS ...
View Course

Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis
Neurology

Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis

This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will highlight strategies to identify and manage spasticity in patients with multiple sclerosis (MS). The expert faculty, Dr. Fred D. Lublin, will first review the unmet needs of multiple sclerosis patients with spasticity. Next, an analysis of current and emerging clinical trial data ...
View Course

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer
Oncology

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer

This CME/CE program will highlight the application of poly (ADP-ribose) polymerase (PARP) inhibitors to improve outcomes for patients with advanced ovarian cancer. The expert faculty, led by Dr. Don Dizon, will first review updates to the National Comprehensive Care Network (NCCN) evidence-based guidelines. Next, an analysis of current and emerging clinical trial data of PARP Inhibitors will be discussed. Following, ...
View Course

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal
Cardiology, Neurology

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal

This CME program is derived from content presented at the 8th European Stroke Organization Conference (ESOC 2022). This educational activity, chaired by Dr. Thorsten Steiner, will review optimal management strategies of patients with anti-FXa-DOAC-associate Intracranial Hemorrhage (ICH). The worldwide utilization of DOACs for a number of different indications has continuously increased over the past decade, and while the anti-FXa DOACS ...
View Course
Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4
Nephrology, Renal

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. In module 3, Dr. George Bakris will analyze the clinical trial data for newer therapeutic options to treat patients with hyperkalemia. Following, Dr. Matthew Weir will lead a faculty discussion to further delve into these trials and how they relate to patient care. Next, ...
View Course

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2
Nephrology, Renal

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. Starting with module 1, Dr. Biff Palmer will review the science of recurrent hyperkalemia, including relationships between dietary potassium intake, serum potassium, and patient morbidities. Next, in module 2, Dr. Pamela Kushner will evaluate the limitations and impact of plant-based diets and potassium restricted ...
View Course

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis
Neurology

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis

This CME program will highlight recent advances in the treatment and management of patients with myasthenia gravis (MG). The expert faculty, Dr. James F. Howard Jr., will first outline the pathophysiology and disease course of MG, referencing the impact of treatment and disease burden on patients. Following, current clinical trial data, including that of complement inhibitor therapies in generalized myasthenia ...
View Course
Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations
Pulmonolgy

Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. William Corrao, will first highlight strategies for early diagnosis and classification of chronic obstructive pulmonary disease (COPD), referencing the current Gold Guidelines. Following, current clinical trial data will be reviewed, and clinical relevance debated in an interactive panel format. Dr. Corrao will ...
View Course
Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics
Pulmonolgy

Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Gregory Tino, will first outline the pathophysiology, prevalence and radiological distribution of non-cystic fibrosis bronchiectasis (NCFBE). Current treatment guidelines and recommendations for patients with NCFBE will be reviewed and an overview of phenotyping provided. Dr. Tino will conclude with an analysis of ...
View Course